메뉴 건너뛰기




Volumn 13, Issue 7, 2011, Pages 639-643

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes

Author keywords

Antidiabetic drug; Clinical trial; Dose response relationship; GLP 1 analogue; Incretin therapy; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; PLACEBO; RECOMBINANT GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; UNCLASSIFIED DRUG;

EID: 79956296360     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01388.x     Document Type: Article
Times cited : (23)

References (10)
  • 1
    • 0141446228 scopus 로고    scopus 로고
    • Enhancing incretin action for the treatment of type 2 diabetes.
    • Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
    • (2003) Diabetes Care , vol.26 , pp. 2929-2940
    • Drucker, D.J.1
  • 2
    • 0035432607 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
    • Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001; 24: 1416-1421.
    • (2001) Diabetes Care , vol.24 , pp. 1416-1421
    • Larsen, J.1    Hylleberg, B.2    Ng, K.3    Damsbo, P.4
  • 3
    • 0043169338 scopus 로고    scopus 로고
    • Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    • Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003; 26: 791-798.
    • (2003) Diabetes Care , vol.26 , pp. 791-798
    • Quddusi, S.1    Vahl, T.P.2    Hanson, K.3    Prigeon, R.L.4    D'Alessio, D.A.5
  • 4
    • 0032976939 scopus 로고    scopus 로고
    • Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    • Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22: 1137-1143.
    • (1999) Diabetes Care , vol.22 , pp. 1137-1143
    • Toft-Nielsen, M.B.1    Madsbad, S.2    Holst, J.J.3
  • 5
    • 0037045845 scopus 로고    scopus 로고
    • Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
    • Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
    • (2002) Lancet , vol.359 , pp. 824-830
    • Zander, M.1    Madsbad, S.2    Madsen, J.L.3    Holst, J.J.4
  • 6
    • 0345017698 scopus 로고    scopus 로고
    • Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
    • Ehlers MR, Klaff LJ, D'Alessio DA et al. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. Horm Metab Res 2003; 35: 611-616.
    • (2003) Horm Metab Res , vol.35 , pp. 611-616
    • Ehlers, M.R.1    Klaff, L.J.2    D'Alessio, D.A.3
  • 7
    • 0037850667 scopus 로고    scopus 로고
    • Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
    • Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377.
    • (2003) Diabetes Care , vol.26 , pp. 2370-2377
    • Fineman, M.S.1    Bicsak, T.A.2    Shen, L.Z.3
  • 8
    • 2342599057 scopus 로고    scopus 로고
    • One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    • Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
    • (2004) Diabetes , vol.53 , pp. 1187-1194
    • Degn, K.B.1    Juhl, C.B.2    Sturis, J.3
  • 9
    • 4644300651 scopus 로고    scopus 로고
    • Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
    • Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 411-417.
    • (2004) Diabetes Metab Res Rev , vol.20 , pp. 411-417
    • Fineman, M.S.1    Shen, L.Z.2    Taylor, K.3    Kim, D.D.4    Baron, A.D.5
  • 10
    • 0027248866 scopus 로고
    • Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
    • Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
    • (1993) Diabetologia , vol.36 , pp. 741-744
    • Nauck, M.A.1    Kleine, N.2    Orskov, C.3    Holst, J.J.4    Willms, B.5    Creutzfeldt, W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.